Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors 1 and 2 in Breast Cancer Cells

SIMPLE SUMMARY: Mebendazole (MBZ), an orally available, FDA-approved anthelmintic, has demonstrated efficacy in reducing solid tumor growth and preventing or treating metastasis in multiple preclinical models of cancer. MBZ was also well tolerated in a recently completed phase I clinical trial. Give...

Descripción completa

Detalles Bibliográficos
Autores principales: Joe, Natalie S., Wang, Yuanfeng, Oza, Harsh H., Godet, Inês, Milki, Nubaira, Riggins, Gregory J., Gilkes, Daniele M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954103/
https://www.ncbi.nlm.nih.gov/pubmed/36831670
http://dx.doi.org/10.3390/cancers15041330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954103/
https://www.ncbi.nlm.nih.gov/pubmed/36831670
http://dx.doi.org/10.3390/cancers15041330

Ejemplares similares